Antifungal agent-161
Antifungal agent-161 (Compound 7) is an Antifungal agent. Antifungal agent-161 potently inhibits Candida albicans ATCC 36082 (with a MIC of 1.32 μM) and Candida glabrata ATCC 2001 (with a MIC of 1.66 μM). Antifungal agent-161 reduces fungal loads in infected mice and eliminates Candida albicans and Candida glabrata infections. Antifungal agent-161 can be used for the research of candidiasis.
For research use only. We do not sell to patients.
- Formula: C26H23Cl3N2
- Molecular Weight:469.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Antifungal agent-161 (0.39-100 μg/mL; 24 h) potently inhibits Candida albicans ATCC 36082 with an MIC of 1.32 μM and Candida glabrata ATCC 2001 with an MIC of 1.66 μM in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Antifungal agent-161 (compound 7) (2 mg/kg; i.p.; daily; 6 days) delivers an 80% survival rate and reduces C. glabrata kidney fungal burden to 337-470 CFU/g in a murine systemic candidiasis model[1].
Antifungal agent-161 (compound 7) (2-20 mg/kg; i.p.) shows no acute toxicity at doses up to 20 mg/kg i.p. in healthy BALB/c mice, with 90-100% survival observed[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 6-8 weeks old, 25-30 g, immunocompromised with cyclophosphamide, inoculated with Candida albicans)[1]
-
Dosage:2 mg/kg
-
Administration:daily; 6 days
-
Result:Achieved an 88% survival rate (vs. 50% in infection control group).
Reduced kidney fungal burden to 228-318 CFU/g (vs. 2100-2300 CFU/g in infection control group).
Preserved intact red and white pulp in spleen tissue with no Candida albicans hyphae.
Maintained intact glomeruli, Bowman's capsules, and convoluted tubules in kidney tissue with only mild collagen dispersion and no visible fungal infestation.
-
Animal Model:BALB/c (female, 6-8 weeks old, 25-30 g, immunocompromised with cyclophosphamide, inoculated with Candida glabrata)[1]
-
Dosage:2 mg/kg
-
Administration:daily; 6 days
-
Result:Achieved an 80% survival rate (vs. 40% in infection control group).
Reduced kidney fungal burden to 337-470 CFU/g (vs. 1670-1850 CFU/g in infection control group).
Preserved intact red and white pulp in spleen tissue with moderate immune cell inflammation and no Candida glabrata infestation.
Maintained intact proximal and distal convoluted tubules, glomeruli, and Bowman's capsules in kidney tissue with normal histology.
Chemical Information
-
Molecular Weight 469.83
-
Formula C26H23Cl3N2
-
SMILES
ClC1=CC=CC(Cl)=C1CN(CC/2)CCC2=C(C3=NC=CC=C3CC4)/C5=C4C=C(C=C5)Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antifungal agent-161 Related Classifications
HY-183308 Related Classifications
Powered by Bioz